Rapid colorimetric detection of p53 protein function using DNA-gold nanoconjugates with applications for drug discovery and cancer diagnostics.

The tumor suppressor protein p53 plays a central role in preventing cancer through interaction with DNA response elements (REs) to regulate target gene expression in cells. Due to its significance in cancer biology, relentless efforts have been directed toward understanding p53-DNA interactions for the development of cancer therapeutics and diagnostics. In this paper, we report a rapid, label-free and versatile colorimetric assay to detect wildtype p53 DNA-binding function in complex solutions. The assay design is based on a concept that alters interparticle-distances between RE-AuNPs from a crosslinking effect induced through tetramerization of wildtype p53 protein (p53-WT) upon binding to canonical DNA motifs modified on gold nanoparticles (RE-AuNPs). This leads to a visible solution color change from red to blue, which is quantifiable by the UV- visible absorption spectra with a detection limit of 5 nM. Contrastingly, no color change was observed for the binding-deficient p53 mutants and non-specific proteins due to their inability to crosslink RE-AuNPs. Based on this sensing principle, we further demonstrate its utility for fast detection of drug-induced DNA binding function to cancer-associated Y220C mutant p53 protein using well-established reactivating compounds. By exploiting the dominant-negative property of mutant p53 over p53-WT and interactions with RE-AuNPs, this assay is configurable to detect low numbers of mutant p53 expressing cells in miniscule sample fractions obtained from typical core needle biopsy-sized tissues without signal attrition, alluding to the potential for biopsy sampling in cancer diagnostics or for defining cancer margins. This nanogold enabled colorimetric assay provides a facile yet robust method for studying important parameters influencing p53-DNA interactions with great promises for clinically pertinent applications.

[1]  Jian Sun,et al.  Colorimetric sandwich immunosensor for Aβ(1-42) based on dual antibody-modified gold nanoparticles , 2017 .

[2]  A. Fersht,et al.  Comparative binding of p53 to its promoter and DNA recognition elements. , 2005, Journal of molecular biology.

[3]  Arunas Ramanavicius,et al.  Magnetic gold nanoparticles in SERS-based sandwich immunoassay for antigen detection by well oriented antibodies. , 2013, Biosensors & bioelectronics.

[4]  Douglas A. Bell,et al.  Probing the Functional Impact of Sequence Variation on p53-DNA Interactions Using a Novel Microsphere Assay for Protein-DNA Binding with Human Cell Extracts , 2009, PLoS genetics.

[5]  A. Fersht,et al.  Quaternary structures of tumor suppressor p53 and a specific p53–DNA complex , 2007, Proceedings of the National Academy of Sciences.

[6]  C. R. Leemans,et al.  Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients , 2004, Clinical Cancer Research.

[7]  Sadia Afrin Khan,et al.  Rapid and sensitive detection of cholera toxin using gold nanoparticle-based simple colorimetric and dynamic light scattering assay. , 2015, Analytica chimica acta.

[8]  T. Haran,et al.  Low-level p53 expression changes transactivation rules and reveals superactivating sequences , 2012, Proceedings of the National Academy of Sciences.

[9]  L. Donehower Using mice to examine p53 functions in cancer, aging, and longevity. , 2009, Cold Spring Harbor perspectives in biology.

[10]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[11]  J. Memelink Electrophoretic mobility shift assay for the analysis of interactions of jasmonic acid-responsive transcription factors with DNA. , 2013, Methods in molecular biology.

[12]  B. Liu,et al.  Hybrid sensor using gold nanoparticles and conjugated polyelectrolytes for studying sequence rule in protein-DNA interactions. , 2013, ACS applied materials & interfaces.

[13]  G. Pfeifer,et al.  In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation , 1997, Oncogene.

[14]  D. Lane,et al.  Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions , 2010, Cell cycle.

[15]  J. Storhoff,et al.  Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. , 1997, Science.

[16]  Xiurong Yang,et al.  Label-free colorimetric immunoassay for the simple and sensitive detection of neurogenin3 using gold nanoparticles. , 2011, Biosensors & bioelectronics.

[17]  Itai Beno,et al.  Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets , 2010, Nucleic acids research.

[18]  E. Orlova,et al.  Two p53 tetramers bind one consensus DNA response element , 2016, Nucleic acids research.

[19]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[21]  Y. Tan,et al.  Study of single-stranded DNA binding protein-nucleic acids interactions using unmodified gold nanoparticles and its application for detection of single nucleotide polymorphisms. , 2011, Analytical chemistry.

[22]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[23]  G. Lahav,et al.  Constant rate of p53 tetramerization in response to DNA damage controls the p53 response , 2014, Molecular systems biology.

[24]  Genxi Li,et al.  Novel method to detect DNA methylation using gold nanoparticles coupled with enzyme-linkage reactions. , 2010, Analytical chemistry.

[25]  K. Kinzler,et al.  Identification and classification of p53-regulated genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Rotter,et al.  Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies , 2011, Cancer Gene Therapy.

[27]  A. Fersht,et al.  Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.

[28]  Jing Bo Zhang,et al.  Analysis of p53 binding to DNA by fluorescence imaging microscopy. , 2012, Micron.

[29]  D. Crothers,et al.  29 Structural and binding properties of DNA response elements bound to p53 proteins and the role of spacer sequences in p53-DNA interactions , 2015, Journal of biomolecular structure & dynamics.

[30]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[31]  Markus O. Zimmermann,et al.  Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 , 2012, Journal of the American Chemical Society.

[32]  J. Koch,et al.  Peptide Arrays on Membrane Supports. Synthesis and Applications , 2002 .

[33]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[34]  Mark R. Servos,et al.  Instantaneous and quantitative functionalization of gold nanoparticles with thiolated DNA using a pH-assisted and surfactant-free route. , 2012, Journal of the American Chemical Society.

[35]  O. Baffa,et al.  Experimental assessment of gold nanoparticle-mediated dose enhancement in radiation therapy beams using electron spin resonance dosimetry , 2015, Physics in medicine and biology.

[36]  P. Hainaut,et al.  Somatic TP53 Mutations in the Era of Genome Sequencing. , 2016, Cold Spring Harbor perspectives in medicine.

[37]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[38]  Yide Mei,et al.  Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression , 2013, Cell Death and Disease.

[39]  L. Mao,et al.  Molecular margin of surgical resections—Where do we go from here? , 2015, Cancer.

[40]  E. Liu,et al.  Gold-nanoparticle-based assay for instantaneous detection of nuclear hormone receptor-response elements interactions. , 2010, Analytical Chemistry.

[41]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[42]  Alan R. Fersht,et al.  Small molecule induced reactivation of mutant p53 in cancer cells , 2013, Nucleic acids research.

[43]  A. Fersht,et al.  Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.

[44]  K. Wong,et al.  Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. , 2016, Cancer research.